leadf
logo-loader
viewGenprex, Inc.

Full interview: Genprex's newly licensed type 1 diabetes gene therapy's potential explained by scientist

Dr George Gittes, Professor of Surgery at the Children's Hospital of Pittsburgh explains how and why he began working on the gene therapy licensed by Genprex (NASDAQ:GNPX).

Dr Gittes says the therapy, currently undergoing pre-clinical studies, has shown data where it caused pancreatic cells to turn into insulin-producing cells.

Quick facts: Genprex, Inc.

Price: 3.48 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $135.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read